NKARTA INC
NKTXNASDAQTrading Snapshot
- Day Range
- $865.53 – $882.34
- 52-Week Range
- $1.70 – $3.72
- Volume
- $1.96B
- Avg Volume
- $1.87B
- Shares Outstanding
- 71.5M
- Next Earnings
- Nov 14, 2026
Fundamentals Snapshot
- Annual Revenue
- $48M
- Last Q Revenue
- $12M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-1.58
- Dividend Yield
- —
- Dilution (1yr)
- +0.6%
Why Investors Own NKTX
- ✓High-growth profile — revenue up +52.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 75% gross margin and 23% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
NKARTA INC
NKTX
StockOtter · stockotter.spaceAbout NKARTA INC
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance
Nkarta (NASDAQ: NKTX) said it expects to present initial clinical data from its autoimmune disease programs at the American College of Rheumatology's 2026 Convergence meeting in November, including presentations in myosi
Nkarta (NASDAQ:NKTX) Stock Falls 3.5% – Here’s Why
Nkarta, Inc. (NASDAQ: NKTX - Get Free Report)'s stock price fell 3.5% during trading on Friday. The stock traded as low as $2.73 and last traded at $2.75. 681,083 shares were traded during trading, an increase of 13% fro
Nkarta to Participate in September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, t
6,300,212 Shares in Nkarta, Inc. $NKTX Acquired by BlackRock Inc.
BlackRock Inc. bought a new stake in Nkarta, Inc. (NASDAQ: NKTX) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 6,300,212 shares of the company
Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) -- Paris, France and New York, USA, July 23, 2026 – Cyllene Therapeutics (“Cyllene Tx”), the global leader in non-replicating HSV-1 (nrHSV-1) vector techno